key: cord-0018847-t93ugn6k
authors: Neuman, Rugina I.; Saleh, Langeza; Verdonk, Koen; van den Meiracker, Anton H.; Russcher, Henk; Metselaar, Herold J.; Visser, Willy; Danser, A.H. Jan
title: Accurate Prediction of Total PlGF (Placental Growth Factor) From Free PlGF and sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1): Evidence for Markedly Elevated PlGF Levels in Women With Acute Fatty Liver of Pregnancy
date: 2021-06-28
journal: Hypertension
DOI: 10.1161/hypertensionaha.121.17258
sha: 0b07c4d19126433f90f9c2ac5cbd26e99e7c16b1
doc_id: 18847
cord_uid: t93ugn6k

Acute fatty liver of pregnancy (AFLP) is characterized by elevated circulating sFlt-1 (soluble Fms-like tyrosine kinase-1), although the free circulating levels of its ligand, PlGF (placental growth factor) are not decreased. Here, we hypothesized that women with AFLP exhibit elevated PlGF production in comparison to women with preeclampsia or hemolysis elevated liver enzymes and low platelet count syndrome. Making use of the well-known mathematical formulas describing drug-receptor interactions, we established that serum total PlGF could be accurately predicted from sFlt-1 and free PlGF levels (n=42; mean calculated K(D) of 50 pmol/L), yielding similar values as the previously published method of thermal dissociation of the sFlt-1-PlGF complexes (r=0.94, P<0.0001). We found that median levels of free PlGF were significantly lower in women with preeclampsia (n=13; 117pg/mL) or hemolysis elevated liver enzymes and low platelet count syndrome (n=12; 59 pg/mL) compared with women without preeclampsia (n=11; 349pg/mL, P<0.0001). In contrast, median total PlGF did not differ between women with no preeclampsia, preeclampsia, and hemolysis elevated liver enzymes and low platelet count syndrome (354 versus 435 versus 344pg/mL), whereas it was markedly elevated in AFLP compared with all groups (2054 pg/mL, P<0.0001). Furthermore, in AFLP, both sFlt-1 and total PlGF declined rapidly postdelivery, with significantly higher predelivery total PlGF (n=12; median, 2054 pg/mL) than postpartum levels (n=14; median, 163pg/mL, P<0.0001), suggesting that in AFLP, PlGF is largely placenta-derived. Collectively, our findings indicate that like sFlt-1, PlGF production is significantly upregulated in AFLP, mainly originating from the placenta. Importantly, total PlGF can now be easily calculated from already available free PlGF and sFlt-1 levels, allowing subsequent evaluation of other groups in whom PlGF is altered.

liver enzymes and low platelet count (HELLP) syndrome, remains a challenge in clinical practice. 2, 3 An important factor underlying this difficulty might be that up to 20% of women with AFLP are also diagnosed with preeclampsia, a condition characterized by hypertension in the second half of pregnancy along with proteinuria or signs of maternal organ damage, including HELLP syndrome. 1, 4, 5 Whether preeclampsia and AFLP are merely associated with one another or belong to a spectrum of the same disorder, as some have suggested, 6, 7 is uncertain.

During preeclampsia, poor placentation triggers the excessive release of the sVEGFR (soluble vascular endothelial growth factor receptor; also known as sFlt-1 [soluble Fms-like tyrosine kinase-1]), which binds its free circulating ligands VEGF and PlGF (placental growth factor). 8, 9 The ensuing angiogenic imbalance is thought to contribute significantly to the clinical manifestations of this disorder. 10 Interestingly, our group has recently discovered that women with AFLP also display increased levels of sFlt-1 in their maternal circulation. 11 Yet, despite the markedly elevated sFlt-1 levels, women with AFLP exhibited higher free levels of PlGF, in contrast to what is observed in HELLP syndrome. 11 Based on our previous observations, we hypothesized that women with AFLP display elevated PlGF production in comparison to preeclampsia/HELLP syndrome. Recently, Lecarpentier et al 12 established a novel method to measure total PlGF in maternal blood because commercial immunoassays only detect the unbound (free) form of PlGF. 12 Hence, in the present study, we intended to (1) validate this method in a small population of women with a low and high sFlt-1/free PlGF ratio; (2) determine whether a more simple approach, by calculating total PlGF mathematically from sFlt-1 and free PlGF, would prove equally reliable as thermal dissociation; and (3) compare serum total PlGF levels in women with AFLP to women with no preeclampsia, preeclampsia or HELLP syndrome. In addition, we explored the origin of the angiogenic markers in AFLP and whether they could derive from the placenta.

All data and supporting materials have been provided within the published article.

Human serum samples from a database of women with singleton pregnancies who had a clinical diagnosis of AFLP at the 

What Is New?

• The levels of total PlGF (placental growth factor) can be accurately predicted from free PlGF and sFlt-1 (soluble Fms-like tyrosine kinase-1) levels using the wellestablished mathematical formulas of drug-receptor interactions. • Placental synthesis of PlGF is significantly increased in acute fatty liver of pregnancy (AFLP) compared with preeclampsia or hemolysis elevated liver enzymes and low platelet count syndrome.

What Is Relevant?

• Total PlGF can now be easily calculated from already available free PlGF and sFlt-1 levels, allowing the evaluation of other groups in whom PlGF might be up-or downregulated.

Total PlGF levels were determined in women with AFLP compared with women without preeclampsia, preeclampsia, and hemolysis elevated liver enzymes and low platelet count syndrome. Calculation of total PlGF using mathematical formulas of drug-receptor interactions was shown to be accurate and yielded similar levels to the recently described method of thermal dissociation. Although total PlGF in preeclampsia and hemolysis elevated liver enzymes and low platelet count syndrome were similar to that in uneventful pregnancies, maternal total PlGF levels in AFLP were greatly elevated compared with all groups. In AFLP, like sFlt-1, total PlGF declined massively after delivery, suggesting that in AFLP, the increased levels of total PlGF are likely placenta-derived. 

We aimed to compare all women with AFLP to 12 gestational age (GA) matched women with either no preeclampsia, confirmed preeclampsia, or HELLP syndrome, given that the values of sFlt-1, free, and total PlGF alter with advancing gestation. 14 Available residual serum samples from these three groups were collected from a previously conducted prospective cohort study in which the sFlt-1/free PlGF ratio was measured in singleton pregnancies with suspected or confirmed preeclampsia, between 2013 and 2016 at 3 hospitals in the Netherlands. This study was approved by the research ethics committee (MEC-2013-202), and written informed consent was obtained from all participants. Venous blood was taken at study entry only and was stored at −80 °C until analysis, which was conducted at the end of the study, to avoid influence on decision making of the obstetricians. 9 Preeclampsia was defined as the presence of new-onset hypertension (systolic blood pressure of ≥140 mm Hg or diastolic blood pressure of ≥90 mm Hg) and proteinuria (protein-to-creatinine ratio ≥30 mg/mmol or ≥300 mg/24 hours or 2+ dipstick) at or after 20 weeks' gestation, according to the 2001 International Society for the Study of Hypertension in Pregnancy definition, which was in effect at the time of study initiation. 15 HELLP syndrome was defined as a reduction of platelet count <100×10 9 /L, an elevation of ALT (alanine aminotransferase) or AST (aspartate aminotransferase) 2-fold the upper limit of normal, and an elevated LDH (lactate dehydrogenase; 2-fold the upper reference limit or >650 IU/L) according to the International Society for the Study of Hypertension in Pregnancy 2013 definition. 16 Women who had a partial HELLP syndrome (≥2 of the HELLP criteria) at time of blood sampling but later developed HELLP syndrome were also considered as HELLP syndrome. Women who were initially suspected of preeclampsia but did not fulfill the diagnosis of gestational hypertension, preeclampsia, or HELLP syndrome throughout their pregnancy were defined as no preeclampsia.

For the validation studies, we selected serum samples from patients with a low angiogenic imbalance (sFlt-1/free PlGF ratio ≤38) versus a high angiogenic imbalance (sFlt-1/free PlGF ratio ≥85) from the abovementioned cohort study. These cutoff values were previously reported to predict the short-term absence of preeclampsia (sFlt-1/free PlGF ratio ≤38) 17 or a high risk of preeclampsia-related adverse outcomes (sFlt-1/ free PlGF ratio ≥85). 18 All pregnancy characteristics and outcome were obtained from digital medical files.

Available serum samples from nonpregnant women with acute liver failure requiring immediate liver transplantation at the Erasmus Medical Center, Rotterdam, the Netherlands, were selected at random, for the measurement of sFlt-1 and total PlGF. The use of these samples for this study was exempted from approval by the local institutional Medical Ethics Committee according to the Dutch Medical Research with Human Participants Law (MEC-2014-060).

Validation Studies rhPlGF (human recombinant PlGF; 264-PGB-010/CF, R&D Systems, Minneapolis, MN) was dissolved in PBS containing 0.1% BSA (PBS). This solution was mixed 1:3 with either PBS or serum to reach a final rhPlGF concentration of 1693 pg/ mL. For comparison, serum samples were also mixed 1:3 with PBS not containing rhPlGF. Serum was obtained from pregnant patients with either a low (≤38) or a high (≥85) sFlt-1/free PlGF ratio. All samples (rhPlGF-containing PBS, serum with PBS, and serum with rhPlGF-containing PBS) were incubated for 30 minutes at room temperature to allow rhPlGF to bind to sFlt-1. Next, sFlt-1 and PlGF were measured in all samples before and after heating.

For the thermal dissociation of all sFlt-1-PlGF complexes, serum samples were placed in a heating block at 70 o C for 10 minutes, as described by Lecarpentier et al. 12 Measurements of sFlt-1 and PlGF before and after heating were performed using the automated Elecsys immunoassay from Roche Diagnostics (Cobas 6000, e-module; Rotterdam, the Netherlands).

In blood plasma, an equilibrium exists between free sFlt-1, PlGF, and their complex, described by the following equation: 

To confirm the method of thermal dissociation, we added rhPlGF (recombinant human PlGF) to serum samples from pregnancies with a low (≤38) or high sFlt-1/ free PlGF ratio (≥85), and measured sFlt-1 and PlGF before and after heating, with and without rhPlGF. Five participants with a ratio ≤38 and 6 participants with a ratio ≥85 were evaluated, whose clinical characteristics and pregnancy outcomes are shown in Table 1 . In participants with a ratio ≤38, serum PlGF levels marginally (P=nonsignificant) increased after thermal dissociation. Heating did not affect the detection of rhPlGF, and also after adding rhPlGF to serum we did not detect higher levels after heating than before ( Figure 1A) .

In contrast, in participants with a ratio ≥85, serum PlGF levels were significantly higher after thermal dissociation than before (270 versus 36 pg/mL). Furthermore, when adding a fixed amount of rhPlGF to serum in this group (ratio ≥85), the levels detected in the absence of heating were significantly lower than the amount that was added (1634 versus 2221 pg/mL). This confirms binding by sFlt-1. Subsequent heating allowed the detection of a PlGF amount that equaled the sum of the added level and the endogenous level (2372 pg/mL; Figure 1A ). Finally, as expected, the sFlt-1 levels were much higher in the ratio ≥85 group, whereas heating greatly diminished the amount of sFlt-1 that could be detected. These data confirm that heating selectively destroys sFlt-1, without affecting PlGF ( Figure 1B) , thus allowing the quantification of total PlGF.

Twelve women with AFLP were compared with women with no preeclampsia (n=11), confirmed preeclampsia (n=13), or HELLP syndrome (n=12). Because most of the women with HELLP syndrome from the previously conducted cohort 9 had a lower GA at blood sampling, we were unable to adequately match the AFLP group to women with HELLP syndrome at a similar GA. All participant characteristics and pregnancy outcomes according to clinical diagnosis are shown in Table 2 Figure 2A ). When comparing free PlGF levels, women diagnosed with preeclampsia and HELLP syndrome displayed lower PlGF values than women with no preeclampsia, whereas free PlGF levels in women with HELLP syndrome were also significantly decreased in comparison to women with AFLP (59 [39-97] pg/mL versus 208 [106-293] pg/ mL; Figure 2B ). In contrast, total PlGF levels (measured after thermal dissociation) did not differ between women with no preeclampsia, preeclampsia, and HELLP Values are median (interquartile range) or n. DBP indicates diastolic blood pressure; GA, gestational age; PlGF, placental growth factor; SBP, systolic blood pressure; sFlt-1 indicates soluble Fms-like tyrosine kinase-1; and uPCR, urinary protein-to-creatinine ratio. syndrome, whereas they were significantly increased in AFLP in comparison to all groups ( Figure 2B) . None of the women were on heparin treatment at time of blood sampling.

K D was calculated in all samples in which we determined both free and total PlGF. This resulted in an average K D (±SEM) value of 50±6.4 pmol/L. Next, we predicted total PlGF in each sample making use of this K D value, and compared it with the actually measured total PlGF value. As can be seen in Figure 2C , this yielded a relationship that was not different from the line of identity (r=0.94, P<0.0001; Figure 2C ).

In 12 women with AFLP, measurements of sFlt-1 and total PlGF were performed antepartum. In 5 of these 12 women, postpartum levels were additionally measured, and in 3 of these 5, postpartum measurements were performed at 2 separate time-points. Additionally, there were 66 women with AFLP in which the values of sFlt-1 and total PlGF were determined postpartum only. Figure 3A and 3B show that the levels of sFlt-1 decreased by >80% within 2 days after delivery, whereas for total PlGF, the drop was even larger, with <10% remaining after 2 days. This pattern was fully confirmed when simply comparing the median levels before delivery with those after, irrespective of the sampling moment (Figure 3C) . The postpartum course of ALT values in AFLP patients was much more gradual ( Figures 3E and 3F ).

Median levels for sFlt-1 were available in 7 patients, whereas total PlGF was measured in 8 patients with liver failure in need of liver transplantation. The clinical characteristics of these patients are shown in Table 3 . All patients were female with a median (interquartile range) of 28 (24-31) years. The most common reason for liver transplantation was toxic or drug-induced liver failure (n=4). Median total PlGF levels of these patients were 22 (12-51) pg/mL, which is comparable to the reference values for free PlGF in healthy nonpregnant women (16 [14] [15] [16] [17] [18] pg/mL; Figure 3D ). 19 In contrast, median sFlt-1 levels (446 [211-1414] pg/mL) were ≈6-fold above the normal range in healthy nonpregnant women (76 [67-84] pg/mL).

In the present study, we established that total PlGF levels in serum can be accurately calculated from the sFlt-1 and free PlGF levels, making use of the well-known mathematical formulas describing drug-receptor interaction. This approach yielded the same levels as the previously published method of thermal dissociation. We confirmed that total PlGF in preeclampsia is similar to that in uneventful pregnancy, although this is also true for HELLP. Yet, in AFLP, maternal total PlGF levels were greatly elevated, both versus women with preeclampsia and HELLP syndrome. Furthermore, in AFLP, total PlGF and sFlt-1 declined rapidly after delivery, suggesting the placenta as their most likely source.

A potential role for sFlt-1 and PlGF in the pathophysiology of AFLP had not been suggested until recently, when our group and others 11, 20 noticed abundantly high circulating sFlt-1 levels in women with this disorder. sFlt-1 is a well-recognized feature of preeclampsia, in which its dramatic rise causes a significant reduction of free circulating PlGF levels. 10 Although a decrease in placental PlGF production has also been suggested to contribute to the low PlGF levels in preeclamptic disease, 21, 22 we observed no differences in total PlGF when comparing women without preeclampsia, preeclampsia, or HELLP syndrome in the current study. This agrees with the view of Lecarpentier et al 12 that decreased free PlGF levels in preeclampsia / HELLP are a consequence of higher sFlt-1 rather than decreased PlGF production of the placenta. 12 With this perspective in mind, our previous observation that despite greater sFlt-1 elevation, free PlGF levels were not reduced in women with AFLP in comparison to women with preeclampsia, was quite surprising. 11 Our present finding that total PlGF levels are significantly raised in women with AFLP now explains this observation.

Obviously, a key question is whether an elevated production or impaired metabolism accounts for the dramatic increases of PlGF in AFLP. Because the relatively small PlGF (MW 34 kD) can readily cross the glomerular filtration barrier, one could hypothesize that its elimination is compromised as renal function declines in AFLP. The observation that total PlGF in women with this disorder decreased rapidly after delivery, despite the persistence of elevated serum creatinine (data not shown), does not support this argument. Another possibility is that the ensuing liver injury and inflammation in AFLP drive increased PlGF production either in the liver or elsewhere. However, our observation that total PlGF is diminished by >90% within 2 days postpartum, whereas the liver recovers more gradually after delivery, indicates that a placental origin or placenta-stimulated PlGF synthesis somewhere else is more probable. Consistent with this hypothesis, serum total PlGF levels in nonpregnant patients with acute liver failure were roughly comparable to the free PlGF levels observed in healthy controls (median [interquartile range], 22 versus 16 [14] [15] [16] [17] [18] pg/mL). Conversely, their sFlt-1 values were 6-fold higher in relation to the reference values of healthy nonpregnant women (76 [67-84] pg/mL). This suggests that liver failure might contribute, at least in part, to the higher sFlt-1 values observed in AFLP, but not to the higher PlGF levels. A partial nonplacental origin of sFlt-1 might also explain why in AFLP women the drop in sFlt-1 levels after delivery was more modest in comparison to that of total PlGF. In both preeclampsia and HELLP, as we have demonstrated before, the opposite is true: sFlt-1 falls by >90% within 2 days, while free PlGF levels off at around 30% to 40% of its predelivery concentrations. Yet, postpartum, the free PlGF levels reach the same nadir in all groups and resemble the total PlGF levels. The simplest explanation of our findings is therefore that the stronger total PlGF drop in AFLP (exceeding that of sFlt-1) is due to its very high predelivery levels. The exact contribution of the different PlGF isoforms (1) (2) (3) (4) to the levels of total PlGF is unknown. Previous studies have indicated that PlGF-1 and PlGF-2 are the main isoforms found in maternal blood, 23, 24 whereas commercial assays mainly measure free PlGF-1. Although differences between assay results may in part be due to different degrees of cross-reactivity, the serum levels of PlGF-1 and PlGF-2 are highly correlated in both normal and pathological pregnancies in all 3 trimesters. 25 This supports their common origin and control mechanisms. It has therefore been suggested that knowledge on the precise contribution of these isoforms may not be of added clinical significance. 25 Accounting for other sFlt-1 binding ligands, such as VEGF, might further improve the accuracy of the predicted total PlGF levels. Ideally, a competitive binding model is set up that takes into account the interaction of all potential binding partners (in particular the various isoforms of both VEGF and PlGF) with sFlt-1. This would require a wide range of assays to measure all these binding partners, as well as knowledge on their affinities for sFlt-1. In reality, we were able to accurately predict total PlGF from sFlt-1 and free PlGF in pregnant women with a considerable variation in clinical background. This would argue against huge variation in VEGF (and thus its capacity to occupy sFlt-1-binding sites) between these conditions. Moreover, current assays provide the levels of sFlt-1 and PlGF only, and thus a simple model with these 2 readily available parameters remains preferred.

The limitations of our study must be addressed. Although the number of women evaluated with AFLP remains limited, this reflects the rarity of this disorder. In addition, we were unable to find women with HELLP syndrome with a similar GA as the women with AFLP. However, if anything, one would expect free PlGF levels to be further decreased in women with HELLP syndrome at a later GA because free PlGF levels start declining from 29 to 32 weeks' gestation until the end of pregnancy. 14 Lastly, it should be taken into account that the pregnancies of women defined as no preeclampsia were not entirely healthy, which might have influenced the interpretation of total PlGF in this population.

At present, it is not known why PlGF production would be so much increased in AFLP. Oxidative stress in placental mitochondria has already been observed in AFLP, 26 and this is widely accepted to upregulate sFlt-1. 10, 27 Moreover, the poor uteroplacental perfusion as a consequence of liver failure and the ensuing hypovolemia in AFLP, is likely to have the same consequence. 2 Yet, in AFLP, unlike preeclampsia, 10 there is no evidence for abnormal placental development. Thus, one plausible theory might be that in AFLP the normal placenta is still able to counteract the increases of sFlt-1 by massively upregulating PlGF. As a consequence, the free PlGF levels in this disorder are in the normal pregnancy range. An alternative scenario could be that the inflammatory response and endothelial disruption following liver injury trigger the release of sFlt-1 and PlGF. Clearly, potential stimuli of sFlt-1 or PlGF, like proinflammatory cytokines and free fatty acids, are worth exploring in AFLP, if possible in liver and placental tissue.

Our study is the first to present a simple mathematical approach to obtain the total PlGF levels. Not surprisingly, our observed K D falls within the binding affinity reported for both PlGF and VEGF in relationship to the Flt-1 receptor (≈20-200 pmol/L). 28, 29 Consequently, total PlGF can now be easily calculated from already available free PlGF and sFlt-1 levels, allowing the subsequent evaluation of other groups in whom PlGF might be upregulated or downregulated, for instance in preeclamptic women with intrauterine growth restriction. In addition, the increased total PlGF concentrations might aid in distinguishing AFLP from other liver disorders of pregnancy, particularly HELLP syndrome. To evaluate this, future studies should firstly validate our findings in a separate cohort of AFLP pregnancies. Values are median (interquartile range) or n. PlGF indicates placental growth factor; and sFlt-1 indicates soluble Fms-like tyrosine kinase-1.

Values represent median (interquartile range) or n (%). AFLP indicates acute fatty liver of pregnancy

HELLP, hemolysis elevated liver enzymes and low platelet count; LD, lactate dehydrogenase

placental growth factor; SBP, systolic blood pressure; sFlt-1, soluble Fms-like tyrosine kinase-1; and uPCR, urinary protein-to-creatinine ratio

Acute fatty liver disease of pregnancy: updates in pathogenesis, diagnosis, and management

Acute fatty liver of pregnancy

Acute fatty liver of pregnancy: clinical outcomes and expected duration of recovery

Acute fatty liver and hellp syndrome: two distinct pregnancy disorders

Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice

Preeclampsia: a microvesicular fat disease of the liver?

Acute fatty liver of pregnancy. A reassessment based on observations in nine patients

Angiogenic markers predict pregnancy complications and prolongation in preeclampsia: continuous versus cutoff values

Preeclampsia: pathogenesis, prevention, and longterm complications

Angiogenic markers are elevated in women with acute fatty liver of pregnancy

Total versus free placental growth factor levels in the pathogenesis of preeclampsia

Physiological changes of pregnancy and the Swansea criteria in diagnosing acute fatty liver of pregnancy

Circulating angiogenic factors and the risk of preeclampsia

The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP)

Introduction to ISSHP new classification of preeclampsia

Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia

Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation

Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia

Markedly higher sFlt-1/PlGF ratio in a woman with acute fatty liver of pregnancy compared with HELLP syndrome

Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

PlGF isoform 3 in maternal serum and placental tissue

Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells

Maternal serum placental growth factor isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks' gestation in late-onset pre-eclampsia and small for gestational age neonates

Liver injury in acute fatty liver of pregnancy: possible link to placental mitochondrial dysfunction and oxidative stress

Placental stress and pre-eclampsia: a revised view

Specificity of vascular endothelial cell growth factor receptor ligand binding domains

Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor